Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02781727 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A Phase 3 study, sponsored by Ascendis Pharma Endocrinology Division A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
NCT02781727 is a Phase 3 study that has completed, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 162 participants.
The verdict
NCT02781727, a Phase 3 study, has completed, sponsored by Ascendis Pharma Endocrinology Division A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
Study Summary
A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial that will be conducted in Armenia, Australia, Belarus, Bulgaria, Georgia, Greece, Italy, New Zealand, Poland, Romania, Russia, Turkey, Ukraine, and the United States.
Interventions
- DRUG Once weekly subcutaneous injection of TransCon hGH
- DRUG Once daily subcutaneous injection of Genotropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2019-01-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02781727
The ClinicalTrials.gov registry entry for NCT02781727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascendis Pharma Endocrinology Division A/S, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Once weekly subcutaneous injection of TransCon hGH is the first listed.
NCT02781727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02781727 about?
NCT02781727 is a clinical study titled "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)". A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be include...
What is the current status of trial NCT02781727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2016-12-13. Estimated completion is 2019-01-17.
What interventions are being tested in trial NCT02781727?
The interventions under investigation include: Once weekly subcutaneous injection of TransCon hGH (DRUG), Once daily subcutaneous injection of Genotropin (DRUG).
Who is sponsoring clinical trial NCT02781727?
This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.